NICE Rejects Revolade For Bleeding Disorders; GSK Considering Its Options
This article was originally published in The Pink Sheet Daily
Executive Summary
UK's cost effectiveness watchdog is uncertain about Revolade's long-term effects and cost
You may also be interested in...
Price Discount Paves The Way For NICE To Clear GSK’s Revolade
U.K. drug cost watchdog NICE has cleared Glaxo’s Revolade and Alcon's Jetrea but rejected Lilly's Alimta as maintenance therapy in a subgroup of lung cancer patients.
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Discount scheme helps draw long-running NICE appraisal of Amgen's Nplate to a positive conclusion.